May 26, 2022

Paracetamol, analgesics not recommended for children after an injection of Covaxin, according to Bharat Biotech


New Delhi: Bharat Biotech, the maker of the indigenous Covid-19 Covaxin vaccine, has released a statement saying that adolescents receiving Covaxin injections do not need to take paracetamol or pain relievers to avoid possible unwanted side effects from the injections.

Paracetamol is an over-the-counter medicine used to treat inflammation and to lower fever. It is commonly used to treat vaccine side effects such as fever or body aches, since the Covid vaccination started in the country last year.

In a statement posted to social media on Wednesday, Bharat Biotech said: “We have received comments that some vaccination centers recommend taking 3 tablets of paracetamol 500 mg with Covaxin for children. No paracetamol or pain reliever is recommended after being vaccinated with Covaxin.

Most of the reported side effects have been mild and “resolve in 1 to 2 days and do not require medication,” the company said.

He further stated that the drugs require consultation with a doctor, and although paracetamol has been recommended with certain other Covid-19 vaccines, it is not recommended for Covaxin.

However, Dr Arun Gupta, pediatrician and chairman of the Delhi Medical Council, told ThePrint: “Paracetamol has been taken with vaccines for decades, as children can often develop a fever after being vaccinated. We recommend that it be given to children only if they develop fever and / or unbearable pain.

“I think what they were trying to make clear is that the systematic or indiscriminate use of paracetamol should not be encouraged,” he added.

The Covaxin clinical trial in children

The Indian government has opened vaccination for 15-18 year olds from January 3. So far, Covaxin is the only vaccine available in India for people in this age group.

Clinical trials of the vaccine for children are still ongoing. On December 30, the company published a declaration on its website saying its Phase 1 and 2 trials for people aged two to 18 have demonstrated “robust safety and immunogenicity.”

The trial, whose results have not yet been published and peer-reviewed, was conducted on 525 eligible participants, of whom 374 reported mild to moderate symptoms after vaccination, most of which resolved within one day. , the company said in its press release.

No serious side effects were reported, the company said, adding that pain at the injection site was the most commonly reported side effect.

(Edited by Poulomi Banerjee)


Read also : As Covid cases rise, CBSE advises schools to ensure students aged 15-18 get vaccinated early